Compare Ginkgo Bioworks Holdings Inc (DNA) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Quantum Computing Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while Quantum Computing Inc trades at $7.44 (market cap $1.69B). The key difference: Quantum Computing Inc is far larger — about 2.2× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Quantum Computing Inc for 25 Days on average.
| DNA | QUBT | |
|---|---|---|
Market Cap | $763.64M | $1.69B |
Volume | 3,204,177 | 7,991,522 |
Sector | Health | Technology |
52-Week High | $15.83 | $21.78 |
52-Week Low | $5.48 | $6.31 |
Typical Hold Time | 7 Days | 25 Days |
Enterprise Value | $865.59M | $753.24M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with negative cash flow. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting ongoing strategic initiatives despite financial challenges.
The outlook remains speculative given persistent losses and cash burn, though analyst consensus is divided. Key risks include execution on revenue growth and path to profitability. Upside depends on successful commercialization of its biotech platform and partnerships, but high volatility and fundamental weakness warrant caution for investors.
QUBT trades at $7.45, down 2.23% on the day, amid a bearish technical signal from moving averages but with oscillators suggesting potential short-term bullish momentum. The company is in a pre-profitability growth phase, with revenue projected to jump to $10 million in 2026 from $682,000 in 2025, though net losses remain substantial. Recent news highlights the launch of the Dirac-3S quantum system and a $42.5 million backlog, indicating commercial progress but ongoing execution risks.
The investment case hinges on QUBT's ability to scale its quantum computing technology and convert its backlog into sustainable revenue, with a consensus analyst price target of $17.33 implying significant upside. Key risks include persistent cash burn, intense competition, and the speculative nature of the quantum computing sector, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
